Three-way Race in Genetic Hearing Loss Therapies... Spotlight on Algenomics
Parallel Development of Three Modalities: AAV, DNA Editing, and RNA Correction
“Personalized Gene Therapy” to Address Diverse Hereditary Hearing Loss Mutations
Algenomics: “Our Goal Is to Derive a First Target Candidate by the Second Half of the Yea
Global pharmaceutical company Eli Lilly is simultaneously targeting the hereditary hearing loss treatment market with three technological approaches. As a strategy to address diverse causative genes and mutation types, it is accelerating platform acquisition by continuing to invest in research and development at the Korean biotech company Alginomics.
According to the industry on the 20th, Lilly is pursuing parallel development of three modalities in the field of genetic hearing loss therapeutics: adeno-associated virus (AAV)-based gene replacement therapy, DNA precision editing, and ribonucleic acid (RNA) correction.
The reason for developing multiple technologies at the same time is that the causative genes of hereditary hearing loss are highly diverse. Because the cause of disease onset differs from patient to patient, Lilly aims to increase treatment efficacy by selecting and applying the most appropriate therapeutic approach according to the mutation type.
The most advanced technology is considered to be the AAV-based gene replacement approach. The candidate drug "AK-OTOF," being developed by Lilly’s subsidiary Akouos, targets congenital hearing loss caused by abnormalities in the OTOF gene. In clinical trial results published in 2024, hearing indicators improved after administering the "AAV1-hOTOF" gene therapy to six pediatric patients with OTOF mutations. However, because this approach replaces a specific defective gene with a normal gene, its applicable patient population is limited. There is also a constraint on the size of genes that can be delivered, which is cited as a drawback because it makes application difficult for some hearing loss–related genes.
DNA gene-editing technology, which directly corrects mutant genes, can fundamentally modify genes and is therefore expected to offer long-term therapeutic effects. Lilly has signed a contract worth up to 1.1 billion dollars (about 1.5909 trillion won) with German biotech Seamless Therapeutics and is pushing ahead with therapeutic development. However, because this technology permanently alters the genome, long-term safety verification remains a critical challenge.
The "trans-splicing ribozyme"-based RNA correction technology being developed by Alginomics restores normal protein expression by cleaving mutant RNA and replacing it with normal RNA. Since it does not directly modify disease-causing DNA but instead corrects only abnormal signals at the RNA stage, it is regarded as relatively safer compared with conventional gene replacement or DNA editing. By targeting a common sequence rather than a single specific mutation, it can simultaneously correct multiple variants and is therefore considered broadly applicable to diseases caused by diverse genetic mutations.
This technology is also designed so that the RNA replacement enzyme is continuously expressed within cells via a viral vector, aiming for long-term correction effects. The key factors are how long this enzyme can be produced stably in the body and how accurately it can be delivered to target cells.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In May last year, Alginomics signed a technology transfer and co-development agreement for an RNA correction platform with Lilly worth up to 1.334 billion dollars (about 1.9286 trillion won), and recently received a portion of the research funding from Lilly. A company representative said, "This receipt of research funding is separate from the upfront payment and signifies that the joint development has entered a full execution phase," adding, "Our goal is to identify a therapeutic candidate for the first hereditary hearing loss target by the second half of this year."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.